Evidence map›Paper›PMID 28456896›Full record

Trial reportInternational journal of clinical oncology2017

The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.

Kazuki Kano, Toru Aoyama, Yukio Maezawa, Tetsushi Nakajima, Kosuke Ikeda, Takanobu Yamada, Tsutomu Sato, Takashi Oshima, Yasushi Rino, Munetaka Masuda and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kazuki KanoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Toru AoyamaDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. t-aoyama@lilac.plala.or.jp.
Yukio MaezawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Tetsushi NakajimaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Kosuke IkedaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Takanobu YamadaDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Tsutomu SatoDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Munetaka MasudaDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Takashi OgataDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Haruhiko ChoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Takaki YoshikawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUpfront surgery and subsequent S-1 chemotherapy is frequently selected for peritoneal cytology-positive (CY1) gastric cancer patients without other distant metastases (CY1-only). The objective of this study was to confirm the efficacy of this strategy in clinical practice and to identify the risk factors associated with survival.

methodsOverall survival (OS) and recurrence-free survival (RFS) were examined in 36 CY1-only patients who underwent macroscopic curative resection followed by postoperative S-1 chemotherapy between January 2000 and June 2015. Univariate and multivariate analyses were performed using a Cox proportional hazards model to identify risk factors.

resultsThe median OS was 22.3 months (95% confidence interval 18.7-31.0). When the OS was compared by a log-rank test, significant differences were observed in the status of lymph node metastasis of pathological N3b (pN3b). Moreover, the univariate and multivariate analyses demonstrated that the status of pN3b was a significant independent risk factor for OS and RFS. The median OS in patients with pathological N0-N3a (pN0-N3a) was 31.0 months, while that in patients with pN3b was 18.2 months (P = 0.002). The median RFS in patients with pN0-N3a was 16.4 months, while that in patients with pN3b was 7.9 months (P = 0.007).

conclusionsThe present study confirmed the efficacy of postoperative S-1 chemotherapy for CY1-only gastric cancer patients who received upfront surgery. This strategy might be recommended as clinical practice for patients with CY1 disease but a more effective treatment should be established for CY1-positive patients, especially for those who are diagnosed with CY1 and pN3b disease.

Indexed as

AgedDisease-Free SurvivalDrug CombinationsFemaleGastrectomyHumansLymphatic MetastasisMaleMiddle AgedOxonic AcidPeritoneal LavagePeritoneal NeoplasmsPostoperative CareProportional Hazards ModelsRisk FactorsStomach NeoplasmsDrug CombinationsOxonic AcidS 1 (combination)TegafurGastrectomyGastric cancerPeritoneal cytologyPostoperative chemotherapyPrognosticator

Identifiers

PMID28456896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.